U.S. Markets close in 3 hrs 48 mins

Chemours' Opteon XL41 Chosen by Carrier to Replace R-410A

Zacks Equity Research

The Chemours Company CC recently announced that its next-generation refrigerant R-454B, sold as Opteon XL41, has been chosen by Carrier as the primary lower Global Warming Potential (GWP) refrigerant. The refrigerant will replace the existing R-410A in ducted residential and light commercial packaged products sold by Carrier in North America, beginning 2023.

Opteon XL41 reduces CO2 emissions by 78% and offers improved energy efficiency compared to R-410A. It also helps in GWP reduction by more than 30% compared to R-32, another industry product to replace R-410A. Notably, Opteon XL41 was particularly designed to achieve maximum GWP reduction to satisfy long-term regulatory requirements.
 
Moreover, Opteon XL41 helps equipment manufacturers achieve lower GWP options that will meet future regulations. Chemours is committed to deliver world-class technology that reduces impact on global climate.

Per Chemours, Opteon XL41 is an ASHRAE Class A2L, hydrofluoro-olefin based refrigerant, selected by Carrier for its energy usage, safety and performance combine with longevity. This product offers customers as a low GWP replacement for R-410A.
 
Chemours offers low GWP solutions portfolio under the brand name of Opteon that delivers the optimal balance of performance, safety and environmental sustainability for commercial refrigeration, heat pumps, chillers and air conditioning.

Shares of Chemours have lost 43.5% in the past six months compared with the industry’s 23.4% decline.



Chemours expects all of its segments to deliver solid year-over-year top- and bottom-line growth. For Fluoroproducts, it expects results to improve on the back of continued adoption of Opteon refrigerants and strong demand for fluoropolymers products.

Moreover, the Chemical Solutions unit is projected to continue delivering improved performance on strong demand for mining solutions products.
Chemours expects the Titanium Technologies segment to witness year-over-year improvement despite expected volume loss due to customer destocking.

Chemours expects adjusted EBITDA within the lower half of the original guidance of $1.70-$1.85 billion. Free cash flow is expected to be roughly $650 million for 2018. Adjusted earnings per share are projected in the range of $5.10-$5.85.

The Chemours Company Price and Consensus

 

The Chemours Company Price and Consensus | The Chemours Company Quote

Zacks Rank & Stocks to Consider

Chemours currently carries a Zacks Rank #3 (Hold).

A few better-ranked stocks in the basic materials space are Verso Corporation VRS, The Mosaic Company MOS and Cameco Corporation CCJ.

Verso has an expected earnings growth rate of 570% for the current year and a Zacks Rank #1 (Strong Buy). The company’s shares have rallied 38.2% in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here.

Mosaic has an expected earnings growth rate of 75.2% for the current year and a Zacks Rank #2 (Buy). The company’s shares have gained 12.8% in the past year.

Cameco has an expected earnings growth rate of 66.7% for the current year and a Zacks Rank #2. Its shares have gained 15.8% in a year’s time.

Looking for Stocks with Skyrocketing Upside?
 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
 
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
 
See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
The Chemours Company (CC) : Free Stock Analysis Report
 
The Mosaic Company (MOS) : Free Stock Analysis Report
 
Cameco Corporation (CCJ) : Free Stock Analysis Report
 
Verso Corporation (VRS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.